← Back to Clinical Trials
Recruiting NCT05681923

NCT05681923 Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05681923
Status Recruiting
Phase
Sponsor University Hospital, Montpellier
Condition Autism Spectrum Disorder
Study Type OBSERVATIONAL
Enrollment 7,320 participants
Start Date 2023-04-19
Primary Completion 2034-03

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
QuestionnairesBiospecimen collectionNeurodevelopmental assessment visit

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 7,320 participants in total. It began in 2023-04-19 with a primary completion date of 2034-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Neurodevelopmental disorders such as attention deficit disorder with or without hyperactivity, autism spectrum disorder, language and social communication disorder, motor coordination disorder, learning disorder (dyslexia, dyscalculia, dysorthography), intellectual development disorder are frequent and long-lasting developmental difficulties that can be observed in children in various domains. They are often associated and have a significant impact on daily functioning at school and at home. The rate of people affected by neurodevelopmental disorders including autism spectrum disorder have increased significantly over the past 20 years. Improved screening only partly explains this evolution. A genetic predisposition plays an important role in the occurrence of these disorders, however, current scientific data suggest a multifactorial origin. Exposures such as those related to the use of pesticides, air pollution or the presence of endocrine disruptors in our diet could be involved in the genesis of neurodevelopmental disorders, particularly during intrauterine life, a period of great vulnerability. The current diagnostic pathways for autism rarely enable the early identification of babies at risk. Without early detection and timely targeted intervention, these children have a poor health outcome and do not reach their full potential. The general objective of the MARIANNE cohort is to constitute a French research infrastructure dedicated to research on the biological and environmental determinants of neurodevelopmental disorders including autism. This cohort is based on the follow-up of 1200 families with already a child affected by an autism spectrum disorder, which implies a high risk of neurodevelopmental disorders including autism spectrum disorder for the siblings, and of 500 families from the general population with no excess risk of neurodevelopmental disorders. The total number of subjects to be included (mother, father, unborn child and ASD sibling for the HR group) is thus 6300. The inclusion of these families will be at the beginning of a new pregnancy and the follow-up will be carried out from the second trimester of pregnancy until the children are 6 years old, the age at which the diagnosis of neurodevelopmental disorders is possible. Biological, clinical, social and environmental data will be collected at different stages of the follow-up and will be included into a large database.

Eligibility Criteria

INCLUSION CRITERIA: General inclusion criteria (High risk and Low risk cohorts) Mother: * Be pregnant (single or multiple pregnancy), at least 16 weeks of amenorrhea, * Have at least one biological child of 24 months or older, * At least 18 years of age Father: * Be the biological father of the unborn child, * At least 18 years of age Unborn Child: \- Have a woman study participant as mother. Specific inclusion criteria for the High risk cohort: * Autistic sibling: refers to the biological child(ren) of the mother and/or father participating in the study and being the parent(s) of the unborn child * Be at least 24 months old and less than 18 years old, * Have a confirmed diagnosis of Autism Spectrum Disorder based on medical records. If in doubt, the SRS-2 (Social Responsiveness Scale for Adults) and PEDS-DM (Parents' Evaluation of developmental status) questionnaires will be completed. Only children with positive scores on one of these questionnaires will be included after validation of the diagnosis by an expert committee, * In case of several children with Autism Spectrum Disorder based in the siblings, only the last born will be included. Remarks: * Autism Spectrum Disorder siblings resulting from a medically assisted procreation are eligible provided that part of the genetic heritage is common to that of the mother or father of the unborn child participating in the study. * If the father does not live with the mother of the unborn child, his participation is not required and does not preclude the participation of other family members. EXCLUSION CRITERIA: General non-inclusion criteria (High risk and Low risk cohorts): Father and mother: * Unable to understand French or the study questionnaires * Participant on protective measures (guardianship or curatorship) or deprived of liberty by judicial or administrative decision, or subject to a legal protection measure * Not affiliated to a social security system * Refusal to participate. In the case of consent given for the born and unborn child, the consent must be given by the person(s) with parental authority. * Live at a distance from the recruitment center incompatible with follow-up. Specific non-inclusion criteria for the Low risk cohort: Mother and/or father of unborn child: \- Have a biological child with a diagnosis of Autism Spectrum Disorder or other neuro developmental disorder

Contact & Investigator

Central Contact

Amaria Baghdadli, MD PhD

✉ a-baghdadli@chu-montpellier.fr

📞 +33 4 67 33 63 83

Frequently Asked Questions

Who can join the NCT05681923 clinical trial?

This trial is open to participants of all sexes, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05681923 currently recruiting?

Yes, NCT05681923 is actively recruiting participants. Contact the research team at a-baghdadli@chu-montpellier.fr for enrollment information.

Where is the NCT05681923 trial being conducted?

This trial is being conducted at Montpellier, France.

Who is sponsoring the NCT05681923 clinical trial?

NCT05681923 is sponsored by University Hospital, Montpellier. The trial plans to enroll 7,320 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology